Nxera Pharma Proposes Changes to its Board of Directors

• Mr. Takeo Morooka nominated for appointment as new External Director
  
• Ms. Miwa Seki and Mr. Noriaki Nagai to retire from the Board of Directors
  

Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated below. The nomination of candidates for External Directors is based on the resolution of the Nomination Committee. The appointments are expected to be ratified officially, subject to the passing of resolutions to be made at the 36th Ordinary General Meeting of Shareholders, scheduled to be held on 25 March 2026.

Chris Cargill, President & CEO of Nxera Pharma, said: “We welcome the appointment of Mr. Morooka as a candidate for External Director of Nxera Pharma. He brings extensive experience in his field, and we expect that, with his deep expertise in regulatory affairs and pharmaceutical policy, he will provide practical and constructive guidance in advancing our medium- to long-term growth strategy and enhancing corporate value, as we further develop Nxera into a leading player in the biopharmaceutical industry. At the same time, we would like to express our sincere gratitude to the outgoing Directors for their many years of dedicated service and significant contributions to the Company’s growth and development.”

1.     Change of Directors
(1)    Content of the Change

	New position	Name	Current position
Appointment	External Director	Takeo Morooka	Strategic Advisory Council
Retirement	-	Miwa Seki	External Director
	-	Noriaki Nagai	External Director

(2)     Curriculum Vitae of a new External Director and Reason for the Appointment
Mr. Takeo Morooka

Apr. 1994	Registered to practice medicine in Japan Resident Physician, Plastic and Reconstructive Surgery, Kyoto University Hospital
Apr. 1998	Medical Officer, Ministry of Health and Welfare, Japan
Jan. 2002	Medical Officer, WHO/HQ
Jan. 2007	Director, Department of Health Facilities Management, International University of Health and Welfare
Feb. 2010	Vice President, Government Affairs, Covidien Japan K.K.
Jul 2015	Head of Health Policy, MSD K.K.
Oct. 2018	Board Director in charge of Operation, Preparatory Committee for the Establishment of Japan Foundation of Medical Isotope Development, General Incorporated (current Board Director) (to the present)
Apr. 2019	Founder and CEO, Japan Medical Isotope Technology Development K.K. (to the present)
Jul 2019	Co-founder and Special Advisor, Fuzionaire RI Technologies K.K. (to the present)
Jan 2020	Co-founder and CEO, Japan Medical Isotope K.K. (to the present)
Jan 2021	Founder and CEO, PH Consulting Ltd. (current Representative Director and President, PH Consulting K.K.) (to the present)
Oct 2021	Co-founder and Executive Officer CSO, Hedgehog MedTech Inc. (to the present)
Dec 2021	Director General, European Federation of Pharmaceutical Industries and Associations, Japan, General Incorporated
Dec 2024	Advisor, MeDiCU Inc. (to the present)
Apr 2025	Strategic Advisory Council Member of Nxera Pharma Co., Ltd. (to the present)